GlassScriptPhysician profile
Brittany Gibbens
NPI 1891126942
$2,872.61
in general payments reported to CMS, 2019-2025
23 companies · $626 in 2025
The $626 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $650 · 2022: $470 · 2023: $498 · 2024: $628 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,752.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,196.46 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $491.50 | 2021-2024 | |
| Lilly USA, LLC | $233.14 | 2021-2024 | Mounjaro |
| Axsome Therapeutics, INC. | $138.78 | 2025 | Auvelity |
| Recor Medical INC | $135.61 | 2025 | Paradise Ultrasound Renal Denervation System |
| Pfizer INC. | $126.43 | 2023-2025 | |
| Medtronic, INC. | $112.72 | 2023 | Venaseal |
| Teva Pharmaceuticals USA, INC. | $87.22 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $72.85 | 2021-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $42.68 | 2021 | |
| Dexcom, INC. | $35.22 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $30.54 | 2021-2023 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $27.30 | 2022-2024 | Spravato |
| Astellas Pharma US INC | $17.65 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $17.07 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $16.41 | 2021 | |
| Philips North America LLC | $15.85 | 2024 | (Ck7) Extended Holter |
| Amarin Pharma, INC. | $15.52 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.15 | 2022 | |
| Averitas Pharma INC. | $14.00 | 2023 | Qutenza |
| Amgen INC. | $13.87 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.10 | 2021 | |
| Genentech USA, INC. | $4.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Gibbens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.